001     287457
005     20241031120341.0
024 7 _ |2 doi
|a 10.3389/fncel.2023.1332179
024 7 _ |2 pmid
|a pmid:38298376
024 7 _ |2 pmc
|a pmc:PMC10827848
024 7 _ |a altmetric:159790193
|2 altmetric
037 _ _ |a DKFZ-2024-00249
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Pizzarelli, Rocco
|b 0
245 _ _ |a Insulin-like growth factor 2 (IGF-2) rescues social deficits in NLG3-/y mouse model of ASDs.
260 _ _ |a Lausanne
|b Frontiers Research Foundation
|c 2024
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1707299793_6045
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Autism spectrum disorders (ASDs) comprise developmental disabilities characterized by impairments of social interaction and repetitive behavior, often associated with cognitive deficits. There is no current treatment that can ameliorate most of the ASDs symptomatology; thus, identifying novel therapies is urgently needed. Here, we used the Neuroligin 3 knockout mouse (NLG3-/y), a model that recapitulates the social deficits reported in ASDs patients, to test the effects of systemic administration of IGF-2, a polypeptide that crosses the blood-brain barrier and acts as a cognitive enhancer. We show that systemic IGF-2 treatment reverses the typical defects in social interaction and social novelty discrimination reflective of ASDs-like phenotypes. This effect was not accompanied by any change in spontaneous glutamatergic synaptic transmission in CA2 hippocampal region, a mechanism found to be crucial for social novelty discrimination. However, in both NLG3+/y and NLG3-/y mice IGF-2 increased cell excitability. Although further investigation is needed to clarify the cellular and molecular mechanisms underpinning IGF-2 effect on social behavior, our findings highlight IGF-2 as a potential pharmacological tool for the treatment of social dysfunctions associated with ASDs.
536 _ _ |0 G:(DE-HGF)POF4-311
|a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |2 Other
|a ASDs
650 _ 7 |2 Other
|a IGF-2
650 _ 7 |2 Other
|a NLG3 -/y mouse
650 _ 7 |2 Other
|a hippocampus
650 _ 7 |2 Other
|a social behavior
700 1 _ |a Pimpinella, Domenico
|b 1
700 1 _ |a Jacobs, Christian
|b 2
700 1 _ |a Tartacca, Alice
|b 3
700 1 _ |a Kullolli, Uarda
|b 4
700 1 _ |0 P:(DE-HGF)0
|a Monyer, Hannah
|b 5
700 1 _ |a Alberini, Cristina M
|b 6
700 1 _ |a Griguoli, Marilena
|b 7
773 _ _ |0 PERI:(DE-600)2452963-1
|a 10.3389/fncel.2023.1332179
|g Vol. 17, p. 1332179
|p 1332179
|t Frontiers in cellular neuroscience
|v 17
|x 1662-5102
|y 2024
856 4 _ |u https://inrepo02.dkfz.de/record/287457/files/fncel-17-1332179.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/287457/files/fncel-17-1332179.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:287457
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-HGF)0
|a Deutsches Krebsforschungszentrum
|b 5
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF4-311
|1 G:(DE-HGF)POF4-310
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Krebsforschung
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2024
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b FRONT CELL NEUROSCI : 2022
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)0320
|2 StatID
|a DBCoverage
|b PubMed Central
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
|d 2021-05-13T10:30:24Z
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
|d 2021-05-13T10:30:24Z
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Anonymous peer review
|d 2021-05-13T10:30:24Z
915 _ _ |0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|a Creative Commons Attribution CC BY (No Version)
|b DOAJ
|d 2021-05-13T10:30:24Z
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)1190
|2 StatID
|a DBCoverage
|b Biological Abstracts
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)1040
|2 StatID
|a DBCoverage
|b Zoological Record
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)9905
|2 StatID
|a IF >= 5
|b FRONT CELL NEUROSCI : 2022
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)0561
|2 StatID
|a Article Processing Charges
|d 2023-10-25
915 _ _ |0 StatID:(DE-HGF)0700
|2 StatID
|a Fees
|d 2023-10-25
920 1 _ |0 I:(DE-He78)A230-20160331
|k A230
|l A230 Klinische Neurobiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A230-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21